Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
PHASE3
162 participants
INTERVENTIONAL
2025-11-28
2026-12-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Methadone
Patients will intraoperatively receive methadone 0.15mg/kg IV, based on ideal body weight.
Methadone Hydrochloride
Patients will intraoperatively be administered methadone 0.15mg/kg IV, based on ideal body weight.
No Methadone
Patients will NOT receive methadone.
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Methadone Hydrochloride
Patients will intraoperatively be administered methadone 0.15mg/kg IV, based on ideal body weight.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Undergoing elective primary total knee arthroplasty with mepivacaine in the spinal anesthesia
Exclusion
* Allergy to methadone or mepivacaine
* Severe liver disease defined as Child's Pugh Class C
* End stage renal disease requiring dialysis
* Known diagnosis of prolonged QT syndrome
* Currently pregnant
* Unable to provide written, informed consent
* Non-English speaking
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Medical University of South Carolina
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
William Barrett
Assistant Professor-Faculty
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
William Barrett, M.D.
Role: PRINCIPAL_INVESTIGATOR
Medical University of South Carolina
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Pro00147447
Identifier Type: -
Identifier Source: org_study_id